Financial information


Introduction


Helix BioPharma’s financial statements and related MD&A are archived on this web site for historical purposes only. Specific information included in these documents may change over time, and may or may not be accurate after the date on the documents. Helix BioPharma has no intention and specifically disclaims any duty to update the information in these documents.

For financial information earlier than the dates listed below, please go to www.sedar.com. Security holders may obtain a hard copy of our audited financial statements free of charge from the Chief Financial Officer of the issuer, by writing to him at: 9120 Leslie Street, Suite 205, Richmond Hill, ON, L4B 3J9, by telephone: 905-841-2300 x233, e-mail: ir@helixbiopharma.com, or fax: 905-841-2244.

YE 2022

Press release | Helix BioPharma Corp. announces fiscal 2022 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2022


AIF | Annual Information Form

Q3 2022

Press release | Helix Biopharma Corp. Announces Fiscal 2022 Third Quarter Results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2022

Press release | Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2022

Press release | Helix BioPharma Corp. announces fiscal first quarter 2022 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2021

Press release | Helix BioPharma Corp. announces fiscal 2021 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2021


AIF | Annual Information Form

Q3 2021

Press release | Helix Biopharma Corp. announces fiscal third quarter 2021 results



MD&A | Management’s Discussion and Analysis of Financial Condition and Results of Operations

Q2 2021

Press release | Helix Biopharma Corp. announces fiscal second quarter 2021 results



MD&A | Management’s Discussion and Analysis of Financial Condition and Results of Operations

Q1 2021

Press release | Helix BioPharma Corp. announces fiscal first quarter 2021 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2020

Press release | Helix BioPharma Corp. announces fiscal 2020 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2020


AIF | Annual Information Form

Q3 2020

Press release | Helix BioPharma Corp. announces fiscal third quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2020

Press release | Helix BioPharma Corp. announces fiscal second quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2020

Press release | Helix BioPharma Corp. announces fiscal first quarter 2020 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2019

Press release | Helix BioPharma Corp. announces fiscal 2019 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2019


AIF | Annual Information Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.

Q3 2019

Press release | Helix BioPharma Corp. announces fiscal third quarter 2019 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2019

Press release | Helix BioPharma Corp. announces fiscal second quarter 2019 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2019

Press release | Helix BioPharma Corp. announces fiscal first quarter 2019 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2018

Press release | Helix BioPharma Corp. announces fiscal 2018 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2018


AIF | Annual Information Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.

Q3 2018

Press release | Helix BioPharma Corp. announces fiscal third quarter 2018 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2018

Press release | Helix BioPharma Corp. announces fiscal second quarter 2018 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2018

Press release | Helix BioPharma Corp. announces fiscal first quarter 2018 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2017

Press release | Helix BioPharma Corp. announces fiscal 2017 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2017


AIF | Annual Information Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.

Q3 2017

Press release | Helix BioPharma Corp. announces fiscal third quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2017

Press release | Helix BioPharma Corp. announces fiscal second quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2017

Press release | Helix BioPharma Corp. announces fiscal first quarter 2017 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2016

Press release | Helix BioPharma Corp. announces fiscal 2016 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2016


AIF | Annual Information Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.

Q3 2016

Press release | Helix BioPharma Corp. announces fiscal third quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2016

Press release | Helix BioPharma Corp. announces fiscal second quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2016

Press release | Helix BioPharma Corp. announces fiscal first quarter 2016 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2015

Press release | Helix BioPharma Corp. announces fiscal 2015 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2015


AIF | Annual Information Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.

Q3 2015

Press release | Helix BioPharma Corp. announces fiscal third quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2015

Press release | Helix BioPharma Corp. announces fiscal second quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2015

Press release | Helix BioPharma Corp. announces fiscal first quarter 2015 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

YE 2014

Press release | Helix BioPharma Corp. announces fiscal 2014 year-end results



MD&A | Management’s discussion and analysis of financial condition and results of operations


Annual report | Annual Report 2014


AIF | Annual Information Form


Proxy circular | Notice of annual and special meeting of shareholders of Helix BioPharma Corp.

Q3 2014

Press release | Helix BioPharma Corp. announces fiscal third quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q2 2014

Press release | Helix BioPharma Corp. announces fiscal second quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations

Q1 2014

Press release | Helix BioPharma Corp. announces fiscal first quarter 2014 results



MD&A | Management’s discussion and analysis of financial condition and results of operations